UWCCC Molecular Tumor Board Registry
Launched by UNIVERSITY OF WISCONSIN, MADISON · Jan 13, 2017
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
The UWCCC Molecular Tumor Board Registry is a clinical trial aimed at understanding how a specialized team can help patients with certain types of cancers, including blood cancers and solid tumors. The study is looking to see how effective this team, known as the Precision Medicine Molecular Tumor Board, is in guiding treatment decisions and improving patient outcomes based on genetic testing of tumors.
To participate in this trial, you must be an adult aged between 65 and 74 years who has been diagnosed with cancer and is undergoing genetic testing. The study is currently recruiting participants of all genders. If you decide to join, you will be asked to read and sign a consent form to ensure you understand the study. It’s important to note that children and adolescents under 18 are not eligible to participate in this trial. If you qualify and choose to take part, you can expect to contribute to valuable research that could improve future cancer care for others.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Clinically suspected or histologically confirmed solid or hematological malignancy
- • Undergoing genetic testing of tumor
- • Ability to understand written informed consent document
- • Willingness to sign written informed consent document
- Exclusion Criteria:
- • Pediatric patients (age\<18 years) will be excluded due to a lack of expertise on the molecular tumor committee
About University Of Wisconsin, Madison
The University of Wisconsin-Madison is a leading research institution renowned for its commitment to advancing healthcare through innovative clinical trials. With a strong emphasis on interdisciplinary collaboration, the university leverages its extensive resources, including cutting-edge facilities and a diverse pool of expert researchers, to conduct rigorous studies that address critical health challenges. The institution's focus on translating research findings into practical applications fosters the development of new treatments and interventions, ultimately contributing to improved patient outcomes and public health initiatives. As a sponsor of clinical trials, the University of Wisconsin-Madison is dedicated to upholding the highest ethical standards and ensuring participant safety throughout the research process.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Madison, Wisconsin, United States
Patients applied
Trial Officials
Mark Burkard, MD, PhD
Principal Investigator
University of Wisconsin, Madison
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials